Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$13.7b

Neurocrine Biosciences Past Earnings Performance

Past criteria checks 4/6

Neurocrine Biosciences has been growing earnings at an average annual rate of 15.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 22.8% per year. Neurocrine Biosciences's return on equity is 11.2%, and it has net margins of 13.2%.

Key information

15.3%

Earnings growth rate

14.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate22.8%
Return on equity11.2%
Net Margin13.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Mar 08
Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Dec 08
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts

Sep 26

Neurocrine to acquire U.K.-based biotech Diurnal

Aug 30

Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial

Aug 05

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Jul 26
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Jul 19

Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Apr 11
Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Revenue & Expenses Breakdown
Beta

How Neurocrine Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NBIX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,8872508880
30 Sep 231,7841918520
30 Jun 231,6731768340
31 Mar 231,599647950
31 Dec 221,4891557530
30 Sep 221,389587260
30 Jun 221,297126950
31 Mar 221,208716550
31 Dec 211,134905830
30 Sep 211,0694455330
30 Jun 211,0323654910
31 Mar 211,0454024450
31 Dec 201,0464074330
30 Sep 201,042934280
30 Jun 201,0062054000
31 Mar 208871773840
31 Dec 19788373540
30 Sep 19675213220
30 Jun 19605182980
31 Mar 19519-392780
31 Dec 18451212490
30 Sep 184141023617
30 Jun 18323-5222032
31 Mar 18233-10620048
31 Dec 17162-1431700
30 Sep 1767-19413790
30 Jun 176-22011188
31 Mar 170-2008490
31 Dec 1615-1416858
30 Sep 1615-1265357
30 Jun 1615-1234758
31 Mar 1615-1073952
31 Dec 1520-893248
30 Sep 1520-792944
30 Jun 1520-602237
31 Mar 1520-501934
31 Dec 140-611832
30 Sep 141-521629
30 Jun 141-471527
31 Mar 142-461426
31 Dec 133-461325
30 Sep 1324-261325
30 Jun 1333-181326
31 Mar 1343-61325

Quality Earnings: NBIX has a large one-off loss of $115.5M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: NBIX's current net profit margins (13.2%) are higher than last year (10.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NBIX's earnings have grown by 15.3% per year over the past 5 years.

Accelerating Growth: NBIX's earnings growth over the past year (61.6%) exceeds its 5-year average (15.3% per year).

Earnings vs Industry: NBIX earnings growth over the past year (61.6%) exceeded the Biotechs industry -8.9%.


Return on Equity

High ROE: NBIX's Return on Equity (11.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.